IVIM Scans for Predicting Metastasis in Sarcoma
What You Need to Know Before You Apply
What is the purpose of this trial?
The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).
Are You a Good Fit for This Trial?
This trial is for adults over 18 with Grade 2 or 3 soft tissue sarcoma larger than 5 cm who are recommended to have radiotherapy before surgery. Participants must understand and sign a consent form. Those with conditions that make MRI scans unsafe cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Biomarker Assessment
Participants undergo MRI and PET imaging to assess hypoxia and collect plasma samples for biomarker analysis
Follow-up
Participants are monitored for distant metastasis-free survival and correlation of biomarkers over time
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor